Lack of antibody affinity maturation due to poor Toll stimulation led to enhanced RSV disease

• Published in: Nature medicine Vol. 15; no. 1; pp. 34 - 41
• Main Authors: Delgado, Maria Florencia, Coviello, Silvina, Monsalvo, A. Clara, Melendi, Guillermina A., Hernandez, Johanna Zea, Batalle, Juan P., Diaz, Leandro, Trento, Alfonsina, Chang, Herng-Yu, Mitzner, Wayne, Ravetch, Jeffrey, Melero, José A., Irusta, Pablo M., Polack, Fernando P.
• Format: Journal Article
• Language: English
• Published: 14-12-2008
• ISSN: 1078-8956; 1546-170X
• DOI: 10.1038/nm.1894

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. A formalin-inactivated RSV vaccine was used to immunize children in 1966 and elicited non-protective, pathogenic antibody. Two immunized infants died and 80% were hospitalized after subsequent RSV exposure. No vaccine was licensed since.
A widely accepted hypothesis attributed vaccine failure to formalin disruption of protective antigens. Instead, we show that lack of protection was not due to alterations caused by formalin, but to low antibody avidity for protective epitopes. Lack of antibody affinity maturation followed poor Toll-like receptor stimulation. This study explains why the inactivated RSV vaccine failed to protect and consequently led to severe disease, hampering vaccine development for forty-two years. Also, it suggests that inactivated RSV vaccines may be rendered safe and effective by inclusion of TLR-agonists in their formulation. In addition, it identifies affinity maturation as a critical factor for the safe immunization of infants.